The first Anti-Ebola vaccine that really works is also a neapolitan success Interview with Rachel Cooper, Global External Communications Manager and Communications and Government Affairs at Glaxo Smith Kline
The first Anti-Ebola vaccine that really works is the result of many years of work of the team of Professor Riccardo Cortese -from Naples- flanked by American researchers, carried out in the laboratories of Okairos in Pomezia -Rome- (Group Glaxo Smith Kline) in collaboration with the IRBM Science Park, CEINGE of Naples, the CNR and the University Federico II. This research, which led to the first vaccine against Ebola, began 14 years ago with an unconventional model of research and development: a vaccine that does not work through the induction of antibodies, but on a genetic logic, and that opens important new experiments aimed at research and development of vaccines to combat other serious epidemics, such as hepatitis c, malaria, avian flu, human flu and tuberculosis. GSK (Glaxo Smith Kline pharmaceutical industry) bought the patent ensuring mass production of the vaccine. We have interviewed Rachel Cooper, Global External Communications Manager and Communications and